$HALB CEO, CTO and YSU's Dr. Sturrus Discuss CDC,
Post# of 630
(Total Views: 197)
Posted On: 04/20/2023 8:47:16 AM
$HALB CEO, CTO and YSU's Dr. Sturrus Discuss CDC, Research Discoveries etc., on "The Street Reports Podcasts"
https://www.accesswire.com/750275/HALB-CEO-CT...Listen-Now
JACKSON CENTER, PA / ACCESSWIRE / April 20, 2023 / Halberd Corporation's (OTC PINK:HALB) President & CEO, William A. Hartman, its Chief Technical Officer, Dr. Mitchell S. Felder, and Youngstown State University (YSU) Professor/lead researcher, Dr. Wm. Gregg Sturrus were interviewed on "The Street Reports" to discuss the company's latest research discoveries and progress on eradicating CDC (Centers for Disease Control and Prevention) provided antibiotic resistant bacteria and deadly fungi.
Listen here: https://thestreetreports.com/halbs-ceo-cto-an...isten-now/
Dr. W. Gregg Sturrus, Chair of the Physics, Astronomy, Geology, and Earth Sciences Department at YSU, is spearheading the laser eradication work, and spoke about the actual lab work and progress in the control of laboratory variables resulting in the successful eradication of various strains of very toxic, antibiotic resistant, bacteria and deadly Candida auris fungi supplied by the CDC.
Dr. Mitchell S. Felder, Chief Technology Officer of Halberd Corporation and inventor of the patented and patent-pending extracorporeal technologies employed by Halberd, provided information on the theoretical basis for the methodology - to physically remove the pathophysiologic basis of the disease without antibiotics. Halberd's experience reveals that no bacteria or pathogen tested to date has develop a resistance to the laser eradication methodology. By employing the laser eradication process extracorporeally, outside the body, it is designed to safely and effectively eliminate disease-causing pathogens without the dangerous side-effects associated with injected or ingested medications.
Dr. Felder also provided information on the recent start of pre-clinical testing at Mississippi State University of Halberd's patent-pending nasal spray intended to block the negative effects of head trauma. The objective is to be able to administer the nasal spray within two hours after head trauma to avoid or minimize long-term brain damage.
William A. Hartman, Chairman, President & CEO, indicated he is most excited about the prospects of developing a product from a proof-of-concept state to a fully functioning therapeutic solution to some of what are considered today's "incurable" diseases and otherwise irreversible consequences of head trauma.
https://www.accesswire.com/750275/HALB-CEO-CT...Listen-Now
JACKSON CENTER, PA / ACCESSWIRE / April 20, 2023 / Halberd Corporation's (OTC PINK:HALB) President & CEO, William A. Hartman, its Chief Technical Officer, Dr. Mitchell S. Felder, and Youngstown State University (YSU) Professor/lead researcher, Dr. Wm. Gregg Sturrus were interviewed on "The Street Reports" to discuss the company's latest research discoveries and progress on eradicating CDC (Centers for Disease Control and Prevention) provided antibiotic resistant bacteria and deadly fungi.
Listen here: https://thestreetreports.com/halbs-ceo-cto-an...isten-now/
Dr. W. Gregg Sturrus, Chair of the Physics, Astronomy, Geology, and Earth Sciences Department at YSU, is spearheading the laser eradication work, and spoke about the actual lab work and progress in the control of laboratory variables resulting in the successful eradication of various strains of very toxic, antibiotic resistant, bacteria and deadly Candida auris fungi supplied by the CDC.
Dr. Mitchell S. Felder, Chief Technology Officer of Halberd Corporation and inventor of the patented and patent-pending extracorporeal technologies employed by Halberd, provided information on the theoretical basis for the methodology - to physically remove the pathophysiologic basis of the disease without antibiotics. Halberd's experience reveals that no bacteria or pathogen tested to date has develop a resistance to the laser eradication methodology. By employing the laser eradication process extracorporeally, outside the body, it is designed to safely and effectively eliminate disease-causing pathogens without the dangerous side-effects associated with injected or ingested medications.
Dr. Felder also provided information on the recent start of pre-clinical testing at Mississippi State University of Halberd's patent-pending nasal spray intended to block the negative effects of head trauma. The objective is to be able to administer the nasal spray within two hours after head trauma to avoid or minimize long-term brain damage.
William A. Hartman, Chairman, President & CEO, indicated he is most excited about the prospects of developing a product from a proof-of-concept state to a fully functioning therapeutic solution to some of what are considered today's "incurable" diseases and otherwise irreversible consequences of head trauma.
(0)
(0)Halberd Corporation (HALB) Stock Research Links
Scroll down for more posts ▼